#ENSI EnSilica PLC – Post Quantum Cryptography Accelerators IP Release January 12, 2024 – Posted in: Vela Technologies Plc (VELA)

EnSilica (AIM: ENSI), a leading chip maker of mixed-signal ASICs (Application Specific Integrated Circuits), is pleased to announce the release of a range of Post-Quantum Cryptography (“PQC”) accelerators, with the first of these intellectual property (“IP”) licenses granted to a major semiconductor supplier. EnSilica is one of the few companies to offer advanced cryptographic accelerators1 to the market as licensable IP cores, expanding EnSilica’s comprehensive range of non-quantum resistant cryptography accelerators for use…

#POLB Poolbeg Pharma – Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick January 17, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

17 January, 2022- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage. In vivo data confirms that this immunotherapy asset targets pan-respiratory virus infections, which…

#ENSI EnSilica PLC – Post Quantum Cryptography Accelerators IP Release January 12, 2024 – Posted in: Vela Technologies Plc (VELA)

#POLB Poolbeg Pharma – Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick January 17, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL